Damian Garde, Allison DeAngelis, and Adam Feuerstein

BioTech

Vertex’s big deal, biotech’s red numbers, & an industry history lesson

How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout

Damian Garde, Allison DeAngelis, and Adam Feuerstein April 11, 2024

BioTech

What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

Who gets to sue the FDA? Is pharma caught in a trade war? And what does “AF” stand for? We cover all that and more

Damian Garde, Allison DeAngelis, and Adam Feuerstein March 28, 2024

BioTech

Live! From the STAT Breakthrough Summit East

Is there a cure for allergies? Has the FDA become too flexible? And which drugs make you muscular? We cover all that and more this

Damian Garde, Allison DeAngelis, and Adam Feuerstein March 21, 2024

BioTech

A dilemma in ALS, the first MASH drug, & why gene therapy is hard

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal? We cover all that

Damian Garde, Allison DeAngelis, and Adam Feuerstein March 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s big deal, biotech’s red numbers, & an industry history lesson

What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

Live! From the STAT Breakthrough Summit East

A dilemma in ALS, the first MASH drug, & why gene therapy is hard

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe